Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
2646 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-03-05 (endpts.com)
Swiss biotech ends Phase 2 study in Alzheimer's shortly after Lilly and Biogen did the same
A small Swiss biotech has terminated a mid-stage test of a new type of oral drug for people with Alzheimer's disease, according to the federal clinical trials database.
Read more
2025-02-19 (tec.mx)
The knowledge economy: the engine that drives global transformation
Discover how Mexico is moving towards a knowledge economy, promoting innovation and technological development. Be part of this change
Read more
2025-02-12 (kathimerini.gr)
The effort to develop research is collapsing
Two more resignations of members of the National Council of Research, Technology and Innovation became known yesterday, which were accompanied by fire against the Ministry of Development.
Read more
2025-02-03 (openpr.com)
Tardive Dyskinesia Treatment Market Report Analysis and Research Studies, Comprehensive Insights and Key Players - Pfizer Inc., Biogen, Novartis AG.
Press release - DataM Intelligence 4Market Research - Tardive Dyskinesia Treatment Market Report Analysis and Research Studies, Comprehensive Insights and Key Players - Pfizer Inc., Biogen, Novartis AG. - published on openPR.com
Read more
2025-01-07 (100x100musica.es)
Drugs for Solid Tumors Market Size, Envisioning Market Evolution (2024-2034) – 100×100 Música
MR Accuracy Reports introduces new research on Drugs for Solid Tumors Market covering the micro level of analysis by competitors and key business segments. The Drugs for Solid Tumors explores a comprehensive study of various segments like opportunities, size, development, innovation, sales, and overall growth of major players. The research is carried out on primary and secondary statistics sources and it consists of both qualitative and quantitative detailing. Some of the major key players profiled in the study are Prudential
Read more
2024-12-12 (marketbeat.com)
Saratoga Research & Investment Management Cuts Stake in Biogen Inc. (NASDAQ:BIIB)
Saratoga Research & Investment Management lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 4.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 150,720 shares of
Read more
2024-11-18 (medicaldevice-network.com)
How decentralisation can fill the gaps in Alzheimer’s research
Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital technologies.
Read more
2024-11-15 (pharmnewskz.com)
Innovative Solutions in Medicine: Game-Changing Research
Kazakhstan Pharmaceutical Bulletin is an information and analytical newspaper for pharmacists. All about the pharmaceutical market. Pharmacy news, pharmaceuticals, pharmacy, healthcare, legislation. Electronic version of KFV
Read more
2024-11-06 (news-medical.net)
Lupus Research Alliance announces 33 studies to be presented at ACR Convergence 2024
The Lupus Research Alliance (LRA), the largest private funder of lupus research worldwide, today announced that a total of 33 studies, funded by the organization or supported by its clinical research affiliate Lupus Therapeutics, will be presented at ACR Convergence 2024.
Read more